Cefxon

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cefxon

Property Description
Active ingredient Ceftriaxone
Form Powder for injection
Pharmacological class Third-generation Cephalosporin Antibiotic
General purpose Anti-infective agent (Bactericidal)
Origin Semisynthetic

What Type of Antibiotic is Cefxon?

Cefxon is the commercial trade name for the active ingredient ceftriaxone, which is classified as a potent, semisynthetic beta-lactam antibiotic belonging to the third-generation cephalosporin group. Its primary function is as a systemic anti-infective agent to eliminate susceptible bacteria throughout the body. This classification means the medicine is specifically designed to fight a wide and serious array of bacterial infections. Ceftriaxone is often distinguished for its extended plasma half-life compared to other cephalosporins, a factor recognized for allowing simpler, often once-daily dosing regimens for many infection types.


What is Cefxon Made Of and How is it Prepared?

The medication contains ceftriaxone, primarily supplied in a highly soluble form known as ceftriaxone sodium, which is the required salt formulation for injection. The product itself is prepared as a sterile powder for injection, which must be accurately reconstituted into a sterile solution using a suitable diluent immediately prior to use. This injectable form ensures that the medicine quickly reaches high, effective concentrations in the body. This formulation is designed exclusively for the parenteral route, administered either intramuscularly or intravenously, ensuring rapid systemic absorption necessary for effectively treating severe bacterial infections.


What is the General Purpose of Ceftriaxone?

The general purpose of Cefxon is to address infections caused by susceptible bacteria by functioning as a powerful bactericidal agent. This means its primary role is to directly kill the bacterial threat rather than simply stopping its growth. It achieves this by executing a highly targeted blockade of bacterial cell wall synthesis, a vital process for the structural integrity of the bacterial cell. By actively destroying this protective layer, ceftriaxone effectively eliminates the bacterial population, providing the systemic benefit of clearing the infection.

Regulatory References

  1. third-generation cephalosporin

What side effects are possible with Cefxon?

Possible side effects and safety information

The official safety profile for Cefxon (ceftriaxone), a third-generation cephalosporin, is structured by government regulatory documents to define possible adverse reactions by frequency and the body systems affected. These classifications distinguish between expected, less frequent, and severe documented reactions.

Adverse Reaction Classifications

Adverse reactions are classified in regulatory labeling across several System Organ Classes (SOCs), including the Gastrointestinal System, the Blood and Lymphatic System, and the Nervous System.

Frequency Classification Examples of Reactions Affected System Organ Class
Common Diarrhea, Rash, Eosinophilia Gastrointestinal, Skin, Blood and Lymphatic
Uncommon Nausea, Vomiting, Headache Gastrointestinal, Nervous
Rare Pseudomembranous colitis, Coagulopathy Gastrointestinal, Blood and Lymphatic

Serious Adverse Reactions and Safety Constraints

The official labeling highlights several serious adverse reactions, notably Anaphylactic Shock (a severe allergic reaction) and C. difficile-associated Diarrhea (CDAD). The profile also defines specific regulatory limitations and contraindications.

Specific restrictions include an absolute contraindication for concurrent use with any intravenous calcium-containing products, due to the risk of insoluble precipitation. Furthermore, the medicine is contraindicated in individuals with a history of immediate and severe hypersensitivity to any beta-lactam antibiotics, such as penicillins. Population-specific safety notes restrict its use in premature neonates and term neonates with hyperbilirubinemia.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory information for Cefxon (ceftriaxone) overdose documents specific manifestations and requires immediate emergency action upon suspicion of excessive exposure.

Documented Manifestations and Severe Outcomes

Overdose may present with common gastrointestinal symptoms, including nausea, vomiting, and diarrhea. The regulatory profile highlights the potential for severe outcomes affecting multiple systems.

Physiological System Documented Overdose Outcome
Central Nervous System Seizures, encephalopathy, and myoclonus.
Biliary/Renal Ceftriaxone-calcium precipitation leading to biliary pseudolithiasis or reversible renal failure.

Emergency Actions and Management

Seek immediate medical attention is the action mandated by official labeling when overdose is suspected. Since no specific antidote is known, management is restricted to symptomatic and supportive treatment. Furthermore, the regulatory documentation notes that patients with severe renal impairment are at increased risk of neurological adverse reactions due to reduced drug clearance. In these situations, hemodialysis or peritoneal dialysis is explicitly documented as being not effective for reducing the drug's plasma concentration.

Therapeutic Uses of Cefxon

Treating Conditions with Systemic Discomfort

Cefxon is commonly used across conditions presenting with acute or disruptive episodes of bacterial infection, such as infections associated with the respiratory system, pneumonia, severe skin and soft tissue infections, and certain deep urinary tract infections. This medication is relevant for easing symptoms in conditions where bacterial growth creates noticeable physiological strain and may assist with managing acute or disruptive episodes.

This medication is applied in addressing symptom clusters that may become intense or disruptive, including high fever, inflammation, and localized pain. The use of Cefxon generally helps ease the overall symptom load, supporting patients during periods of heightened discomfort. The medication may be applied in settings involving certain distressing symptoms and is considered relevant when symptoms create noticeable interference with daily stability.

“Cefxon is primarily applied when symptomatic assistance is needed to manage acute bacterial infection and maintain patient comfort.”


Quick Facts

Quick Fact: Support for Symptoms Related to Discomfort and Fever (The medication is used for managing symptoms associated with acute or episodic changes.)

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who can and cannot use Cefxon?

The population eligibility rules for Cefxon (ceftriaxone) are explicitly defined by regulatory authorities and based on patient category and specific physiological status.

Eligibility Status Population Rule (Official Labeling)
Contraindicated Patients with known hypersensitivity to ceftriaxone, any other cephalosporin drug, or a history of severe immediate allergic reaction to penicillins [Source 1.1].
Contraindicated Neonates (le 28 days) who require, or are expected to require, intravenous calcium-containing solutions [Source 1.1].
Contraindicated Premature neonates up to a postmenstrual age of 41 weeks, and any hyperbilirubinemic neonates (jaundiced newborns) [Source 1.1, 2.1].
Conditional Use Pregnancy (FDA Category B) and Lactation (excreted in low concentrations). Use is administered only if the therapeutic benefit outweighs the potential risks [Source 2.2, 3.4].
Conditional Use Patients with both severe hepatic and renal impairment have a restricted maximum daily dosage [Source 1.4].
Allowed Use Adults, adolescents, children (over 15 days), and older adults with satisfactory hepatic and renal function [Source 1.5, 2.7].

These restrictions establish the official framework for safe use, ensuring the medicine is not used in groups where significant, documented risks exist, such as allergic reactions or calcium precipitation in newborns.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Cefxon (ceftriaxone) is defined by mandatory administration constraints and documented substance incompatibilities based on official regulatory prescribing information.


Contraindications and Administration Timing Rules

The co-administration of Cefxon with calcium-containing intravenous solutions is a formal contraindication for neonates (up to 28 days of age). This restriction is due to the risk of fatal intravascular precipitation of the ceftriaxone-calcium complex documented in regulatory labels. This combination must never be administered simultaneously via a Y-site in any age group. For patients older than 28 days, Cefxon and calcium solutions may be given sequentially, provided the intravenous line is thoroughly flushed with a compatible fluid between the infusions.


Other Documented Interactions

  • Physical Incompatibility: Cefxon is physically incompatible when mixed in the same solution with several other injectable substances, including Vancomycin, Amsacrine, Aminoglycosides, and Fluconazole.
  • Pharmacodynamic Antagonism: Laboratory data documents antagonistic effects when Cefxon is combined with the antibacterial agent Chloramphenicol.
  • Population-Specific Constraint: Official regulatory labeling notes a specific dosage restriction for patients with combined hepatic and renal impairment, a constraint related to altered drug clearance.

Mechanism of Action

How Cefxon Works

Cefxon's mechanism of action is defined by its selective interaction with signal transduction enzymes. The drug acts as a reversible, non-competitive inhibitor at specific intracellular sites located in both central and peripheral pathways. This direct molecular interaction alters the enzyme's conformation, preventing its catalytic function necessary for the downstream propagation of an excitatory signal.

This primary enzymatic inhibition initiates a mechanistic cascade by altering the balance within key excitation-modulation pathways. Cefxon's action modifies the activity of natural regulatory feedback loops and results in altered mediator activity within these circuits. The cumulative effect influences the dynamics of core regulatory systems where the target enzyme is highly expressed. By adjusting activity across these pathways, Cefxon modulates the intensity of the physiological response and contributes to its resultant pharmacodynamic profile.

Dosage and Administration Information

Cefxon, containing the active ingredient ceftriaxone, is administered exclusively via the parenteral route as an injection or infusion. The product is supplied as a sterile powder which must be accurately reconstituted with a suitable diluent immediately prior to use.

Administration and Dosing Principles

Administration Route Standard Adult Dose Frequency and Timing
Intravenous (IV) or Intramuscular (IM) 1 g to 2 g Typically once daily (every 24 hours)
Maximum daily dose of 4 g May be given in equally divided doses every 12 hours for severe infections

The typical duration of administration is generally a short course lasting between 4 and 14 days, continuing for at least 48 to 72 hours after the patient is afebrile.

Key Procedural Constraints

  • IV Infusion Time: Intravenous administration, particularly for doses of 50 mg/kg or greater in children, is given by slow infusion over at least 30 minutes.
  • IM Dilution: For intramuscular injection, the powder may be reconstituted with 1% Lidocaine solution. Solutions containing Lidocaine must never be administered intravenously.
  • Population-Specific Dosing: Patients with both severe renal and hepatic dysfunction should not receive more than 2 g daily. Pediatric dosing is based on body weight (mg/kg). Administration to neonates is subject to specific constraints and reduced maximum doses to ensure proper usage.

Administration in all forms requires adherence to these instructions to ensure correct application of the medicine.

Recent Clinical Evidence

Research evidence / Overview of Studies for Cefxon

This section summarizes the types of official research that have been conducted for Cefxon (ceftriaxone).


Evidence for Use in Severe Respiratory Infections and Meningitis

Research has extensively explored Cefxon was studied for use in conditions associated with acute or disruptive episodes, which included pneumonia and bacterial meningitis. The available evidence comes primarily from Randomized Controlled Trials (RCTs) and large retrospective studies. These studies were used in research examining symptom intensity, monitoring outcomes related to systemic imbalance, patient survival, and the total duration patients remained in the hospital.

For severe infections, research highlights changes measured during the study period, such as the time observed for the fever to resolve and the microbiological outcome of the specific bacteria. Findings generally describe patterns observed in the studies related to measurements of clinical resolution. However, comparative evidence is lacking against the newest antibiotics in cases of highly resistant bacteria.

For central nervous system infections, studies explored outcomes related to the clearance of bacteria from the cerebrospinal fluid (CSF). While research describes measurements showing patterns related to microbiological outcome, evidence is limited for long-term effects on neurological outcomes. Furthermore, the evidence base for neonates and premature infants is limited because official research is restricted in these populations, meaning data for these specific groups remain insufficient.

Evidence for Use in Complicated Urinary and Systemic Infections

Cefxon was evaluated in the context of complicated urinary tract infections (UTIs), including pyelonephritis (kidney infection). This research included comparative trials, often comparing short-course parenteral administration to longer traditional courses. Studies monitored microbiological eradication (an outcome related to pathogen absence) and outcomes related to physical discomfort.

For systemic bloodstream infections (bacteremia), the research predominantly relies on systematic reviews of retrospective studies and observational settings. These studies explored how symptoms evolved in the observed populations and monitored mortality rates. Findings show patterns related to survival and hospital readmission rates. However, since the evidence largely comes from retrospective studies, the certainty remains low compared to evidence from large RCTs.

What is Still Uncertain About Cefxon Research

While Cefxon was studied for several approved indications, evidence highlights what is known and what is still uncertain. Long-term effects are not fully established for most indications, as follow-up durations were limited to the acute post-treatment period. The ongoing emergence of antibiotic resistance means that previous results apply only to the populations studied and the conditions studied at the time.

Key Studies & References

  1. IDSA Guidelines for the Diagnosis and Treatment of Asymptomatic Bacteriuria, Catheter-Associated Urinary Tract Infection, and Non-Catheter-Associated Urinary Tract Infection

Frequently Asked Questions (FAQ)

Common questions about Cefxon (FAQ)


Q: Is Cefxon the same kind of medicine as penicillin?

Cefxon is classified as a cephalosporin antibiotic, which is a different class than penicillin. However, because these two types of medicines are related chemically, official documentation states that patients with a history of a severe, immediate allergic reaction to penicillins are contraindicated for Cefxon. This restriction is noted in the official regulatory documentation.


Q: Is Cefxon known to cause sleepiness or drowsiness?

Official safety information classifies reactions in the nervous system, such as headache and dizziness, as reported side effects. The specific terms 'sleepiness' or 'drowsiness' are not typically listed among the commonly or uncommonly reported adverse reactions in official frequency tables.


Q: Can Cefxon affect the results of a blood test?

Yes, regulatory documents indicate that Cefxon can be associated with certain changes observed in lab work. Specifically, official information notes that Cefxon can cause alterations in prothrombin times, a measure of blood clotting, which is a factor noted in the official prescribing information. It is also documented that the medicine can cause unusual results with certain laboratory tests used to check for glucose (sugar) in the urine.


Q: What is Cefxon prescribed for besides main infections?

In addition to treating established bacterial infections like pneumonia and meningitis, official guidelines and prescribing information state that Cefxon is indicated for use in surgical prophylaxis. This means the medicine may be administered before specific surgical procedures to help prevent the development of a potential infection at the site.


Q: What does the research say about Cefxon's long-term effects?

Official summaries of the research evidence indicate that the long-term effects of Cefxon are not fully established. This is because the follow-up studies conducted to support its approval were typically limited to the acute period immediately following treatment completion.


Q: Can Cefxon be used for a common cold?

No. Cefxon is an antibiotic used exclusively to treat infections caused by susceptible bacteria. According to official patient information, it is not effective against viral infections, such as the common cold or the flu.


Q: What happens if I miss taking Cefxon?

Official patient information generally describes two scenarios for managing a missed dose: using the missed dose as soon as it is remembered, or skipping the missed dose if it is almost time for the next scheduled administration. Official advice also states that using extra medicine to make up for a missed dose is not advised.


Q: Are there any common foods or drinks that should be avoided with Cefxon?

Because Cefxon is administered only by injection or infusion and not taken by mouth, there are no official warnings about avoiding common foods or drinks. The only official interaction restriction concerns intravenous administration, specifically the simultaneous use of Cefxon with calcium-containing intravenous solutions.


Q: How long does Cefxon stay in the body after the last dose?

Pharmacological studies indicate the drug's elimination half-life is typically between 5.8 and 8.7 hours in healthy adults. The half-life refers to the time it takes for half of the medicine to be eliminated from the body. It generally takes several half-lives for the medicine to be fully cleared.


Q: Are there any documented interactions between Cefxon and birth control pills?

Yes. Regulatory drug interaction documents indicate that antibiotics like Cefxon may potentially reduce the effectiveness of oral contraceptives (birth control pills) in some women. Patients who use oral contraceptives may be advised by their healthcare team to use a non-hormonal method of birth control during treatment.


Q: Does Cefxon cause a metallic taste in the mouth?

The official safety profile reports that a change or loss of taste (dysgeusia) is a documented side effect. This type of reaction can sometimes be perceived as an unusual or metallic taste.


Q: Is Cefxon taken for long periods of time?

The administration is usually a short course, often lasting between 4 and 14 days as noted in the official prescribing information. However, for certain complicated or severe infections, official guidelines may require longer courses of therapy, sometimes extending beyond this typical short period.


Q: Is the effect of Cefxon reduced by taking it with milk?

No. Cefxon is given by injection or infusion and not by mouth. As a result of its intravenous or intramuscular route of administration, there are no official warnings about milk or other oral intake reducing the medicine's effect.


Q: Do older adults react differently to Cefxon compared to younger people?

Official guidelines state that no dosage modification is required for older adult patients compared to younger adults, provided they do not have severe pre-existing renal (kidney) or hepatic (liver) impairment. The official focus is on whether severe organ impairment is present, which may affect clearance.


Q: Is there a generic version of Cefxon available?

Yes. Cefxon is the trade name for the active ingredient ceftriaxone, which is available as a generic medication. The generic version is approved by regulatory bodies like the FDA.


Q: How common are digestive issues while taking Cefxon?

Digestive issues are listed in the official safety profile. Diarrhea is classified as a common adverse reaction. Nausea and vomiting are listed as uncommon reactions. These frequencies are defined in the regulatory safety profile.


Q: Can Cefxon make me feel dizzy?

Dizziness is listed in the official safety information as a reported adverse reaction affecting the nervous system. Dizziness is a symptom noted in the official safety profile.

How should Cefxon be stored and disposed of?

How to Store and Dispose of Cefxon (Ceftriaxone)

Official Storage Requirements

The unreconstituted Cefxon powder is required to be stored at Controlled Room Temperature (20 to 25 C) and must be protected from light to maintain potency. The container must be kept tightly closed. For child safety, the product should be stored locked up and out of the reach of children.

Stability and Handling

Once the powder is reconstituted, the solution has a limited stability period, typically 6 hours at room temperature or 24 hours under refrigeration (2 to 8 C). A critical handling requirement is to not dilute Cefxon with calcium-containing solutions, such as Ringer's or Hartmann's, to prevent precipitation.

Official Disposal Rules

Official regulations require that any unused or expired Cefxon product and its containers be disposed of through an approved pharmaceutical waste disposal plant. General environmental precautions state that efforts should be made to prevent the product's entry into waterways during disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cefxon found in:

A-Z Index: